The FDA approved nivolumab as adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer.

CHICAGO — Adjuvant osimertinib conferred a significant OS benefit vs. placebo among patients with resected, EGFR-mutant, stage IB to IIIA non-small cell lung cancer, according to results of the ...

Osimertinib and Resected EGFR-Mutated NSCLC. 2023-07-13. DOI: 10.1056/NEJMdo007151 Save. Permissions ...

Patients, with resected pancreatic cancer who had completed standard-of-care chemotherapy, received 3 bi-weekly injections of MesoPher and booster injections at 4 and 7 months.

Key Takeaways. Opdivo and Yervoy improve cure rates in resected stage 3/4 melanoma compared to placebo, with Opdivo showing superior efficacy. CheckMate 238 and EORTC 18071 trials reveal Opdivo's cure ...

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic ...

Alectinib in Resected ALK-Positive NSCLC. 2024-04-11. DOI: 10.1056/NEJMdo007451 Save. Permissions ...

IFN alpha-2b prolongs the relapse-free interval and overall survival of high-risk resected melanoma patients. The increment in median disease-free survival (from 1 to 1.7 years) and overall survival ...

US Food and Drug Administration approves Opdivo® (nivolumab) as adjuvant treatment for eligible patients with completely resected stage IIB or stage IIC melanoma. Bristol Myers Squibb. October 13 ...

Increasing number of patients with borderline resectable (BL) or locally advanced (LA) disease are treated with pre-operative (Pre-Op) CT with FFX. However, the benefit of Post-Op CT after Pre-Op FFX ...